FrancophonIA/ELRC3.0 huggingface dataset:
English: When given to dogs at three to five times the recommended dose, injection site reactions characterised by erythema and oedema occurred.
Estonian: Soovitatud annusest kolm kuni viis korda suurema annuse manustamisel tekkisid koertel süstekohal reaktsioonid punetus ja turse.
English: SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Estonian: ERINÕUDED ETTEVAATUSABINÕUDE OSAS KASUTAMATA JÄÄNUD PREPARAADI VÕI SELLE JÄÄTMETE, KUI NEID TEKIB, HÄVITAMISEL
English: Prior to use, gently shake the vial to resuspend the product.
Estonian: Enne kasutamist tuleb ravimit veidi loksutada selle taassuspendeerimiseks.
English: Prolonged-release suspension for injection
Estonian: Annustamisintervalli pikendamine
English: Methylcellulose Sodium carboxymethylcellulose Polysorbate 60
Estonian: Naatriumkarboksümetüültselluloos Polüsorbaat 60
English: Sodium chloride Chlorocresol
Estonian: Klorokresool
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Vältida silma ja nahale sattumist.
English: • If the dog is both clinically normal and has a normal Na
Estonian: • Kui koera kliiniline seisund on 25. päeval normaalne ja ka Na
English: This product may cause pain and swelling at the injection site if accidentally self-administered.
Estonian: Juhuslikul ravimi manustamisel iseendale võib see ravim põhjustada valu ja turset süstekohal.
English: PACKAGE LEAFLET: Zycortal 25 mg/ml prolonged-release suspension for injection for dogs
Estonian: PAKENDI INFOLEHT Zycortal 25 mg/ml toimeainet prolongeeritult vabastav süstesuspensioon koertele
English: Zycortal 25 mg/ml prolonged-release suspension for injection for dogs
Estonian: Zycortal 25 mg/ml toimeainet prolongeeritult vabastav süstesuspensioon koertele
English: Active substance: Desoxycortone pivalate 25 mg/ml
Estonian: Toimeaine: desoksükortoonpivalaat 25 mg/ml
English: desoxycortone pivalate 25 mg/ml
Estonian: desoksükortoonpivalaat 25 mg/ml
English: SPECIAL WARNING(S)
Estonian: suhe normaalne (s.t
English: Re-evaluate the dog and measure the serum sodium/potassium ratio (Na⁺/K⁺ ratio) approximately 10 days after the first dose (which is the time to maximum concentration (Tmax) of desoxycortone).
Estonian: Ligikaudu 10 päeva möödumisel esimesest annusest (mis on desoksükortooni maksimaalse plasmakontsentratsioonini tekkimiseks kuluv aeg (Tmax) tuleb hinnata koera uuesti ja mõõta tema naatriumi/kaaliumi suhet (Na⁺/K⁺ suhe) seerumis ).
English: Zycortal 25 mg/ml prolonged-release suspension for injection desoxycortone pivalate
Estonian: Zycortal 25 mg/ml toimeainet prolongeeritult vabastav süstesuspensioon desoksükortoonpivalaat
English: Zycortal 25 mg/ml prolonged-release suspension for injection for dogs Desoxycortone pivalate
Estonian: Zycortal 25 mg/ml toimeainet prolongeeritult vabastav süstesuspensioon koertele desoksükortoonpivalaat
English: Invented name Strength Pharmaceutical form
Estonian: Tugevus Ravimvorm
English: Route of administration Packaging Content
Estonian: Pakendi sisu kontsentratsioon)
English: Fifty of the patients in this study survived.
Estonian: Viiskümmend patsienti jäid selles uuringus elama.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cyanokit on 31 November 2007.
Estonian: Euroopa Komisjon andis Cyanokiti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 31. Novembril 2007.
English: The full EPAR for Cyanokit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cyanokiti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Cyanokit?
Estonian: Mis meetmed võetakse, et tagada Cyanokiti ohutu ja efektiivne kasutamine?
English: The maximum total dose is 10 g for adults, and 140 mg/kg in children up to a maximum of 10 g.
Estonian: Maksimaalne koguannus täiskasvanutel on 10 g ja lastel 140 mg/kg, kuni maksimaalselt 10 g-ni.
English: A risk management plan has been developed to ensure that Cyanokit is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Cyanokiti võimalikult ohutu kasutamine.
English: Cyanokit hydroxocobalamin
Estonian: Cyanokit hüdroksokobalamiin
English: It is given as an infusion over 15 minutes.
Estonian: Seda manustatakse 15 minutit kestva infusioonina.
English: The information on these patients was obtained from their medical notes, as recorded in databases at two French hospitals.
Estonian: Nende patsientide teave saadi nende haiguslugudest Prantsusmaa kahe haigla andmebaasides.
English: Other information about Cyanokit
Estonian: Muu teave Cyanokiti kohta
English: The use of Cyanokit can interfere with the assessment of burns and with laboratory test results.
Estonian: Cyanokiti kasutamine võib häirida põletuste hindamist ja laboratoorsete testide tulemusi.
English: Symptoms of brain damage resolved in 38 of 66 patients.
Estonian: Ajukahjustuse sümptomid kadusid 38 patsiendil 66-st.
English: This helps to reduce the effects of cyanide poisoning.
Estonian: See aitab tsüaniidimürgistuse mõju vähendada.
English: Cyanokit is given as an emergency treatment as soon as possible after poisoning.
Estonian: Cyanokiti manustatakse erakorralise ravimina niipea kui võimalik pärast mürgistust.
English: Cyanokit is given along with other appropriate decontamination and supportive measures, including providing oxygen for the patient to breathe.
Estonian: Cyanokiti manustatakse koos muude sobivate dekontaminatsiooni- ja toetusmeetmetega, sealhulgas varustatakse patsienti hingamiseks hapnikuga.
English: The response was unknown in the remaining 13 patients.
Estonian: Ülejäänud 13 patsiendi ravivastus ei ole teada.
English: This can be attached to the patient's notes so that hospital staff are made aware of these effects of the medicine.
Estonian: Selle võib kinnitada patsiendi haigusloole, et haigla personal oleks ravimi neist toimetest teadlik.
English: In the study of smoke inhalation, the response to Cyanokit was assessed as ‘positive' in 31 patients (45%), ‘partial' in 15 (22%) and ‘absent' in 10 (15%).
Estonian: Suitsu sissehingamise uuringus hinnati ravivastust Cyanokitile 31 patsiendil (45%) positiivseks ja 15-l (22%) osaliseks ning 10-l (15%) ravivastus puudus.
English: It contains the active substance hydroxocobalamin (vitamin B12a).
Estonian: See sisaldab toimeainena hüdroksokobalamiini (B12a-vitamiin).
English: The frequency of the other side effects of Cyanokit cannot be estimated with the information currently available.
Estonian: Cyanokiti muude kõrvalnähtude sagedust ei ole võimalik praegu kättesaadava teabe alusel hinnata.
English: This makes it a useful option when cyanide poisoning is only suspected.
Estonian: Seega on see kasulik valik juhtudel, mil on vaid tsüaniidimürgistuse kahtlus.
English: In this study, the patients' condition at the accident scene was compared with that at the end of the infusion of Cyanokit and over the following three days.
Estonian: Selles uuringus võrreldi patsientide seisundit õnnetuskohal seisundiga Cyanokiti infusiooni lõpus ja kolmel järgmisel päeval.
English: Hydroxocobalamin (vitamin B12a) has been used as a vitamin supplement since the 1950s.
Estonian: Hüdroksokobalamiini (B12avitamiini) kasutatakse vitamiinilisandina alates 1950. aastatest.
English: The second dose is given over a period of between 15 minutes and two hours, depending on the patient's condition.
Estonian: Teine annus manustatakse olenevalt patsiendi seisundist 15 minuti kuni kahe tunni jooksul.
English: Therefore, the CHMP decided that Cyanokit's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Cyanokiti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: However, the CHMP concluded that Cyanokit had advantages over alternative antidotes because it has a good safety profile in patients who have not been poisoned.
Estonian: Komitee leidis siiski, et Cyanokitil on alternatiivsete antidootidega võrreldes eeliseid, sest sellel on hea ohutusprofiil patsientide puhul, kes ei ole mürgistust saanud.
English: Cyanide poisoning usually results from exposure to smoke from fire, from breathing or swallowing cyanide, or from getting it onto the skin or mucous membranes (moist body surfaces, such as the lining of the mouth).
Estonian: Tsüaniidimürgistust põhjustab tavaliselt tule suits, tsüaniidi sissehingamine või allaneelamine või tsüaniidi kokkupuude naha või limaskestaga (näiteks suu limaskestaga).
English: For adults, the initial dose is 5 g. For children, it is 70 mg per kilogram body weight up to a maximum dose of 5 g. A second dose can be given, depending on how severe the poisoning is and how well the patient is responding.
Estonian: Täiskasvanutel on algannus 5 g. Lastel on see 70 mg kehakaalu kilogrammi kohta kuni maksimaalse annuseni 5 g. Olenevalt mürgistuse raskusest ja patsiendi ravivastusest tohib manustada ka teise annuse.
English: A further 14 patients were studied whose cyanide poisoning was due to something other than smoke inhalation; most of these patients had taken cyanide during a suicide attempt.
Estonian: Uuriti veel 14 patsienti, kelle tsüaniidimürgistus oli põhjustatud muust kui suitsu sissehingamisest; enamik neist patsientidest olid manustanud tsüaniidi enesetapukatsel.
English: For more information about treatment with Cyanokit, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cyanokitiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Two patients survived despite their hearts having stopped before receiving Cyanokit.
Estonian: Kaks patsienti jäid ellu, kuigi nende süda oli enne Cyanokiti manustamist seiskunud.
English: Because hydroxocobalamin has an intense red colour, most patients will have dark red colouring of the skin and mucous membranes for up to 15 days and of the urine for up to 35 days after receiving Cyanokit.
Estonian: Hüdroksokobalamiini erksa punase värvuse tõttu värvuvad enamikul patsientidest pärast Cyanokiti manustamist nahk ja limaskestad kuni 15 päevaks ja uriin kuni 35 päevaks tumepunaseks.
English: Information on its effectiveness was obtained in 83 patients who had been admitted to hospital with suspected cyanide poisoning and who received Cyanokit.
Estonian: Ravimi efektiivsuse teavet saadi 83 patsiendi andmetest, kes said tsüaniidimürgistuse kahtluse tõttu haiglaravi ja keda raviti Cyanokitiga.
English: In one study of 69 patients, cyanide poisoning was due to exposure to smoke from fire.
Estonian: Ühes 69 patsiendiga uuringus oli tsüaniidimürgistus põhjustatud tule suitsust.
English: There is no information available on success rates with other antidotes for cyanide poisoning, so it was not possible to carry out a comparison between the success rates seen with Cyanokit and with alternatives.
Estonian: Tsüaniidimürgistuse muude antidootide edukuse kohta andmed puuduvad, seega ei olnud võimalik Cyanokiti edukust alternatiivsete ravimitega võrrelda.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cyanokit, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Cyanokiti omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Survival was more likely in those who received Cyanokit before their hearts had stopped, who had less severe symptoms of brain damage and who had lower blood cyanide levels.
Estonian: Ellujäämise tõenäosus oli suurem patsientidel, kellele manustati Cyanokiti enne nende südame seiskumist, kellel olid ajukahjustuse sümptomid kergemad ja kelle veres oli tsüaniiditase madalam.
English: Cyanokit is used as an antidote to treat known or suspected poisoning with cyanide, a highly poisonous chemical.
Estonian: Cyanokiti kasutatakse antidoodina tsüaniidi kui väga mürgise keemilise aine teadaoleva või oletatava mürgistuse raviks.
English: This is a summary of the European public assessment report (EPAR) for Cyanokit.
Estonian: See on ravimi Cyanokit Euroopa avaliku hindamisaruande kokkuvõte.
English: Of the 14 patients whose cyanide exposure was due to something other than smoke inhalation, 10 survived, including seven patients with ‘lethal' levels of cyanide in the blood.
Estonian: 14 patsiendist, kelle tsüaniidimürgistus oli põhjustatud muust kui suitsu sissehingamisest, jäid ellu 10, sealhulgas seitse patsienti, kelle tsüaniiditase veres oli surmav.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cyanokit.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This lowers cyanide levels in the body and stops the cyanide fixing itself to an enzyme in cells called cytochrome oxidase, which is important for providing energy in cells.
Estonian: Selle tulemusena väheneb tsüaniidi tase kehas ning tsüaniid ei kinnitu enam rakkudes ensüümi tsütokroomoksüdaasi külge, mis on tähtis rakkude varustamiseks energiaga.
English: What is Cyanokit?
Estonian: Mis on Cyanokit?
English: The four who died had high blood levels of cyanide, and either their hearts had stopped or they had stopped breathing before receiving Cyanokit.
Estonian: Neljal surnud patsiendil oli tsüaniiditase veres kõrge ning enne Cyanokiti manustamist oli nende süda seiskunud või nad olid lakanud hingamast.
English: Why has Cyanokit been approved?
Estonian: Miks Cyanokit heaks kiideti?
English: The active substance in Cyanokit, hydroxocobalamin, reacts with cyanide in the body to form cyanocobalamin, a non-poisonous compound that is removed from the body in the urine.
Estonian: Cyanokiti toimeaine hüdroksokobalamiin reageerib kehas tsüaniidiga, misjärel tekib mittetoksiline ühend tsüanokobalamiin, mis väljub kehast uriiniga.
English: For the full list of all side effects reported with Cyanokit, see the package leaflet.
Estonian: Cyanokiti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Cyanokit is a powder to be made up into a solution for infusion (drip) into a vein.
Estonian: Cyanokit on pulber, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: What is the risk associated with Cyanokit?
Estonian: Mis riskid Cyanokitiga kaasnevad?
English: The CHMP concluded that Cyanokit appeared to be a well-tolerated and efficient cyanide antidote, based on its effects on survival and the prevention of brain damage.
Estonian: Inimravimite komitee otsustas, et lähtudes Cyanokiti mõjust elulemusele ja ajukahjustuste ennetamisele, näib see olevat hästi talutav ja efektiivne tsüaniidi antidoot.
English: There have been no studies directly comparing Cyanokit to any other treatment in humans.
Estonian: Cyanokiti võrdlemiseks muude ravimitega ei ole inimestel otseselt uuringuid läbi viidud.
English: How is Cyanokit used?
Estonian: Kuidas Cyanokiti kasutatakse?
English: What benefit has Cyanokit shown during the studies?
Estonian: Milles seisneb uuringute põhjal Cyanokiti kasulikkus?
English: What is Cyanokit used for?
Estonian: Milleks Cyanokiti kasutatakse?
English: How does Cyanokit work?
Estonian: Kuidas Cyanokit toimib?
English: A sticker explaining this is supplied with every pack of Cyanokit.
Estonian: Cyanokiti turustataval pakendil on sellekohase selgitusega kleebis.
English: How has Cyanokit been studied?
Estonian: Kuidas Cyanokiti uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Cyanokit on retseptiravim.
English: The CHMP took these comments into account.
Estonian: Inimravimite komitee võttis neid märkusi arvesse.
English: The decentralised procedures UK/H/6034/001/DC, UK/H/6035/001/DC and UK/H/6176/001/DC started on 23 July 2015.
Estonian: Detsentraliseeritud menetlused UK/H/6034/001/DC, UK/H/6035/001/DC ja UK/H/6176/001/DC algatati 23. juulil 2015.
English: The reference Member State (RMS) is the United Kingdom and the concerned Member States (CMS) Austria (AT), Germany (DE), Croatia (HR), Ireland (IE), Luxembourg (LU), France (FR), Belgium (BE), Netherlands (NL), Portugal (PT) and Spain (ES).
Estonian: Viiteliikmesriik on Ühendkuningriik ja asjaomased liikmesriigid Austria (AT), Saksamaa (DE), Horvaatia (HR), Iirimaa (IE), Luksemburg (LU), Prantsusmaa (FR), Belgia (BE), Madalmaad (NL), Portugal (PT) ja Hispaania (ES).
English: Based on clinical data provided by the applicant, no new safety issues have been identified.
Estonian: Taotleja esitatud kliiniliste andmete põhjal ei ole kindlaks tehtud uusi ohutusprobleeme.
English: It is worth noting that the indication being sought is for short term (3 days) exposure.
Estonian: Tasub märkida, et taotletav näidustus on lühiajaliseks kasutamiseks (3 päeva).
English: All the risks associated with prolonged use have been identified as safety concerns in the current risk management plan.
Estonian: Kõik pikaajalise kasutamisega seostatavad riskid on kehtivas riskijuhtimiskavas loetletud ohutusprobleemidena.
English: Risk management
Estonian: Riskijuhtimine
English: The proposed combination therefore offers an alternative therapeutic option to such opioid based combinations.
Estonian: Kavandatav kombinatsioon pakub seega ravialternatiivi sellistele opioididel põhinevatele kombinatsioonidele.
English: The applicant presented literature search strategy.
Estonian: Taotleja esitas andmed kirjandusväljaannete otsingust.
English: It is noted that there is significant use of opioid combinations in the EU.
Estonian: Opioidseid kombinatsioonravimeid kasutatakse ELis märkimisväärselt palju.
English: A risk management plan has been submitted in line with the above.
Estonian: Eespool kirjeldatut arvesse võttes on esitatud riskijuhtimiskava.
English: • The Committee considered the notification of the referral initiated by the United Kingdom under Article 29(4) of Directive 2001/83/EC on the basis that France, Germany, Spain and The Netherlands considered that the granting of the marketing authorisation would constitute a potential serious risk to public health.
Estonian: • komitee arutas direktiivi 2001/83/EÜ artikli 29 lõike 4 kohast Ühendkuningriigi algatatud esildismenetlust, mis tugines Prantsusmaa, Saksamaa, Hispaania ja Madalmaade arvamusele, et müügiloa andmine kujutaks endast võimalikku tõsist ohtu rahvatervisele;
English: More importantly this is consistent with the post marketing experience of the use of the combination both world-wide and in the countries within the EU.
Estonian: Mis veelgi olulisem: kõrvalnähtude profiil vastas kombinatsiooni kasutamisega seotud turustamisjärgsetele kogemustele nii kogu maailmast kui ka ELi liikmesriikidest.
English: These risks are well known and are controlled by routine pharmacovigilance practices which CHMP has endorsed.
Estonian: Need riskid on hästi teada ja neid hoitakse kontrolli all inimravimite komitee heakskiidetud ravimijärelevalvetoimingute abil.
English: Having considered all the data submitted by the applicant, the CHMP considered that the benefit-risk balance was adequately demonstrated.
Estonian: Pärast kõigi taotleja esitatud andmete läbivaatamist oli inimravimite komitee seisukohal, et kasulikkuse ja riski tasakaal on piisavalt tõendatud.
English: Overall benefit-risk balance
Estonian: Üldine kasulikkuse ja riski tasakaal
English: Thirdly, there is a medical need for a new fixed dose combination analgesic that does not contain an opioid component for relief of acute pain.
Estonian: Kolmandaks on olemas meditsiiniline vajadus uue fikseeritud annusega valuvaigistava kombinatsioonravimi järele, mis ei sisaldaks ägeda valu vaigistamiseks opioidset ainet.
English: On 21 October 2016 the RMS United Kingdom therefore triggered a referral under Article 29(4) of Directive 2001/83/EC as these issues were considered to be a potential serious risk to public health.
Estonian: Seetõttu algatas Ühendkuningriik 21. oktoobril 2016 direktiivi 2001/83/EÜ artikli 29 lõike 4 kohase esildismenetluse, väites, et need probleemid võivad oluliselt ohustada rahvatervist.
English: The use of the fixed combination will give time to both patients and physicians before an opioid containing product will be used.
Estonian: Fikseeritud annusega kombinatsioon annab patsientidele ja arstidele aega, enne kui kasutusele võetakse opioidi sisaldav ravim.
English: They all seem numerically similar to each other; however no formal comparison between the active substances was performed.
Estonian: Toimeainete arvandmed tunduvad sarnased, kuid selles uuringus ei toimunud toimeainete formaalset võrdlust.
English: As at the CMDh procedure no agreement could be reached the procedure was referred to the CHMP.
Estonian: Et koordineerimisrühma menetluses kokkulepet ei saavutatud, tehti esildis inimravimite komiteele.
English: As the proposed fixed dose combination is recommended to be used for no more than 3 days, the potential for prolonged use is largely mitigated.
Estonian: Kuna fikseeritud annusega kombinatsiooni ei soovitata kasutada kauem kui 3 päeva, võib pikaajalise kasutamise tõenäosust pidada väikeseks.
English: Therefore such a potential has virtually no impact on the benefit-risk status of the medicinal product.
Estonian: Seetõttu ei mõjuta see ravimi kasulikkuse ja riskide tasakaalu peaaegu üldse.
English: The applicant noted also the PSUR reports which cover over 89 million tablets of market use have not suggested any additional or unexpected risks.
Estonian: Taotleja juhtis tähelepanu ka sellele, et perioodilised ohutusaruanded (turustamisjärgsed kogemused enam kui 89 miljoni tabletiga) ei ole viidanud täiendavatele ega ootamatutele riskidele.
English: The results showed that the combination provided significantly greater pain relief than either mono-component (p<0.001).
Estonian: Tulemused näitasid, et kombinatsioonil oli oluliselt parem valuvaigistav toime kui kummalgi toimeainel eraldi (p < 0,001).
English: Rationale for use of the fixed dose combination ratio
Estonian: Fikseeritud annusega kombinatsiooni kasutamise põhjendus
English: The CHMP took these comments into account, and considered that with the additional amendments to the product information for the restriction of use to maxim of 3 days, and the additional data provided for special populations including the elderly, that the overall safety of this fixed-dese combination to be acceptable in the indication for the short-term symptomatic treatment of mild to moderate pain.
Estonian: Inimravimite komitee võttis neid märkusi arvesse ning oli arvamusel, et pidades silmas ravimiteabes tehtavaid täiendavaid muudatusi seoses kasutusaja piiramisega maksimaalselt 3 päevale ning eripopulatsioonide, sh eakate kohta esitatud lisaandmeid, peetakse selle fikseeritud annusega kombinatsiooni üldist ohutust kerge kuni mõõduka valu lühiajalise sümptomaatilise ravi näidustusel vastuvõetavaks.
English: • The Committee concluded by majority that the benefit risk balance of this medicinal product in the short-term symptomatic treatment of mild to moderate pain is favourable.
Estonian: • komitee enamuse nõusolekul järeldati, et kõnealuse ravimi kasulikkuse ja riski tasakaal kerge kuni mõõduka valu lühiajalises sümptomaatilises ravis on positiivne.
English: The secondary analyses showed either no difference or in favour of the combination.
Estonian: Teisestes analüüsides kas erinevust ei täheldatud või osutus kombinatsioon efektiivsemaks.